Impact of angiotensin blockade on response to PD1/L1 inhibitors for patients with metastatic urothelial carcinoma (mUC).

被引：0
|
作者：
Skelton, William Paul [1 ]
Jain, Rohit K. [2 ]
Curran, Catherine [3 ]
Pond, Gregory Russell [4 ]
Naqvi, Syeda Mahrukh Hussnain [5 ]
Kim, Youngchul [1 ]
Nuzzo, Pier Vitale [3 ]
Abou Alaiwi, Sarah [3 ]
Nassar, Amin [6 ]
Jain, Rakesh K. [7 ]
Sonpavde, Guru [8 ]
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[2] Lee Moffitt Canc Ctr, Tampa, FL USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] McMaster Univ, Dept Oncol, Hamilton, ON, Canada
[5] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[6] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA
[7] Massachusetts Gen Hosp, Boston, MA 02114 USA
[8] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 06期
关键词：
D O I：
10.1200/JCO.2021.39.6_suppl.453
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
453
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Impact of concurrent angiotensin inhibitors on outcomes with PD1/L1 inhibitors for patients (pts) with metastatic urothelial carcinoma (mUC).
    Agarwal, Archana
    Pond, Gregory Russell
    Curran, Catherine
    Nassar, Amin
    Nuzzo, Pier Vitale
    Kumar, Vivek
    McGregor, Bradley Alexander
    Wei, Xiao X.
    Harshman, Lauren Christine
    Choueiri, Toni K.
    Kilbridge, Kerry L.
    Sonpavde, Guru
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [2] Angiotensin Blockade Modulates the Activity of PD1/L1 Inhibitors in Metastatic Urothelial Carcinoma
    Jain, Rohit K.
    Skelton IV, William Paul
    Pond, Gregory Russell
    Naqvi, Mahrukh
    Kim, Youngchul
    Curran, Catherine
    Freeman, Dory
    Nuzzo, Pier Vitale
    Abou Alaiwi, Sarah
    Nassar, Amin H.
    Jain, Rakesh K.
    Sonpavde, Guru
    CLINICAL GENITOURINARY CANCER, 2021, 19 (06) : 540 - 546
  • [3] Impact of Renin-Angiotensin System Inhibitors on Response to PD1/L1 Inhibitors in Patients With Metastatic Renal Cell Carcinoma
    Fortune, Kathryn
    Ali, Soham
    Masur, Jack
    Viscuse, Paul
    Devitt, Michael
    Dreicer, Robert
    Skelton, William Paul
    CLINICAL GENITOURINARY CANCER, 2025, 23 (01)
  • [4] Impact of renin-angiotensin system inhibitors on response to PD1/L1 inhibitors in patients with metastatic renal cell carcinoma (mRCC)
    Fortune, Kathryn
    Ali, Soham
    Masur, Jack
    Viscuse, Paul Vincent
    Devitt, Michael Edward
    Dreicer, Robert
    Skelton, William Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 424 - 424
  • [5] Impact of concurrent medications on outcomes with PD1/PD-L1 inhibitors for metastatic urothelial carcinoma.
    Agarwal, Archana
    Pond, Gregory Russell
    Curran, Catherine
    Nassar, Amin
    Nuzzo, Pier Vitale
    Kumar, Vivek
    McGregor, Bradley Alexander
    Wei, Xiao X.
    Harshman, Lauren Christine
    Choueiri, Toni K.
    Kilbridge, Kerry L.
    Sonpavde, Guru
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [6] EphrinB2 (B2) expression predicts poor response to PD1/L1 antibodies (Ab) in metastatic urothelial carcinoma (mUC).
    Sadeghi, Sarmad
    Siddiqi, Imran
    Ashouri, Karam
    Tsao-Wei, Denice D.
    Cogan, Jon P.
    Jackovich, Alexandra
    Chennapan, Krithika
    Freeman, Dory
    O'Toole, Jillian
    van Bokhoven, Adrie
    Torkko, Kathleen
    Gill, Inderbir
    Gill, Parkash S.
    Flaig, Thomas W.
    Sonpavde, Guru P.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [7] Association of ephrinB2 (B2) expression on overall survival (OS) and resistance to PD1/L1 inhibitors (inh) in metastatic urothelial carcinoma (mUC)
    Sadeghi, Sarmad
    Mar, Nataliya
    Tsao-Wei, Denice
    Ashouri, Karam
    Siddiqi, Imran
    Cogan, Jon P.
    Jackovich, Alexandra
    Freeman, Dory
    O'Toole, Jillian
    Flaig, Thomas W.
    Gill, Parkash S.
    Rezazadeh, Arash
    Sonpavde, Guru P.
    Bellmunt, Joaquim
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] Serial changes in PD1/PDL1 expression in metastatic urothelial carcinoma (mUC) patients (pts) treated with immune checkpoint blockade (CPB).
    Tzeng, Alice
    Diaz-Montero, C. Marcela
    Rayman, Patricia A.
    Kim, Jin Sub
    Pavicic, Paul G.
    Finke, James
    Barata, Pedro C.
    Lamenza, Marcelo
    Devonshire, Sarah
    Schach, Kim
    Emamekhoo, Hamid
    Ernstoff, Marc S.
    Hoimes, Christopher J.
    Rini, Brian I.
    Garcia, Jorge A.
    Gilligan, Timothy D.
    Ornstein, Moshe Chaim
    Grivas, Petros
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (05)
  • [9] DNA damage repair and response (DDR) gene alterations (alt) and response to PD1/PDL1 blockade in platinum treated metastatic urothelial carcinoma (mUC).
    Teo, MinYuen
    Seier, Kenneth
    Ostrovnaya, Irina
    Regazzi, Ashley Marie
    Kania, Brooke Elizabeth
    Moran, Meredith Maisie
    Cipolla, Catharine Kline
    Bluth, Mark J.
    Chaim, Joshua
    Al-Ahmadie, Hikmat
    Solit, David B.
    Funt, Samuel
    Wolchok, Jedd D.
    Iyer, Gopa
    Charen, Alexandra Snyder
    Bajorin, Dean F.
    Rosenberg, Jonathan E.
    Callahan, Margaret K.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [10] Clinical Outcomes of Platinum-ineligible Patients with Advanced Urothelial Carcinoma Treated With First-line PD1/L1 Inhibitors
    Pond, Gregory R.
    Agarwal, Archana
    Ornstein, Moshe
    Garcia, Jorge
    Gupta, Ruby
    Grivas, Petros
    Drakaki, Alexandra
    Lee, Jae-Lyun
    Kanesvaran, Ravindran
    Di Lorenzo, Giuseppe
    Verolino, Pasquale
    Barata, Pedro
    Bilen, Mehmet A.
    Hussain, Syed A.
    Curran, Catherine
    Sonpavde, Guru
    CLINICAL GENITOURINARY CANCER, 2021, 19 (05) : 425 - 433
12345